Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMBD-001 in NRG1-fusion or HER3-mutated solid tumors
NCT05919537Phase 1Active, not recruiting
- Sponsor
- Hummingbird Bioscience
- Start
- Sep 2023
- Primary completion
- Mar 2031
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of hmbd-001 in solid tumor (advanced stage), pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) (4 arms), sponsored by Hummingbird Bioscience. Primary endpoints: Incidence and Nature of Adverse Events, Incidence and nature of dose-limiting toxicities and 1 more. Started Sep 2023; status: active, not recruiting.
02
Drugs
hmbd-001
03
Conditions
solid tumor (advanced stage)pancreatic ductal adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05919537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05919537.